Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

Rhea-AI Summary

Lifecore Biomedical (NASDAQ: LFCR) will participate in the 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum on March 17–18, 2026. Management, including Mr. Josephs, will host a fireside chat at 9:00–9:35am ET on March 17 and will meet with investors.

A live webcast of the fireside chat will be accessible via Lifecore’s Investor Events & Presentations page, with a replay available on the company website after the conference.

News Market Reaction – LFCR

-1.30%

-1.30% Session close to close

In the Mar 11 session, LFCR declined 1.30%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights LFCR’s ongoing investor outreach through participation in the KeyBanc H...

Analysis

This announcement highlights LFCR’s ongoing investor outreach through participation in the KeyBanc Healthcare Virtual Forum, including a fireside chat on March 17, 2026. It follows recent CDMO agreements and index inclusion, reinforcing a narrative of business development and visibility-building. From a fundamentals standpoint, investors may track how management discusses revenue growth to $31,109 thousand, progress on narrowing the $3,067 thousand operating loss, management of the 20.9% related-party term loan, and any plans related to the existing resale shelf registration.

Key Figures

Total revenue: $31,109 thousand Prior-year revenue: $24,705 thousand Gross profit: $7,791 thousand +5 more

8 metrics

Total revenue $31,109 thousand Quarter ended September 30, 2025 (Q3 2025 10-Q)

Prior-year revenue $24,705 thousand Quarter ended September 30, 2024 (comparison in Q3 2025 10-Q)

Gross profit $7,791 thousand Quarter ended September 30, 2025 (Q3 2025 10-Q)

Operating loss $3,067 thousand Quarter ended September 30, 2025 (Q3 2025 10-Q)

Net loss $9,991 thousand Quarter ended September 30, 2025 (Q3 2025 10-Q)

Loss per share $0.29 Quarter ended September 30, 2025 (Q3 2025 10-Q)

Cash and equivalents $18,856 thousand As of September 30, 2025 (Q3 2025 10-Q)

Term-loan interest rate 20.9% Effective annual rate on related party term loan (Q3 2025 10-Q)

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 04	CDMO agreement	Positive	-0.6%	New Indomo agreement to supply DT-001 batches for anticipated Phase 2 trials.
Feb 17	Conference participation	Neutral	+1.1%	Announcement of meetings and presence at DCAT Week 2026 in New York.
Jan 16	Equity inducement grants	Neutral	+0.4%	Inducement RSUs and options granted to newly hired employees.
Dec 18	Index inclusion	Positive	-0.6%	Planned addition to the Nasdaq Biotechnology Index following reconstitution.
Dec 17	Major CDMO deal	Positive	+9.9%	CDMO master services agreement with a new large multinational pharma customer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has been mostly positive or strategic, with a mix of aligned and divergent price reactions, suggesting investors sometimes fade favorable headlines.

Recent Company History

Over the last several months, LFCR has reported multiple business and corporate milestones. These include a CDMO master services agreement with a new large multinational customer on Dec 17, 2025, upcoming inclusion in the Nasdaq Biotechnology Index announced on Dec 18, 2025, and a new development services agreement with Indomo disclosed on Mar 4, 2026. The company also frequently announces participation in industry events, such as DCAT Week 2026. Today’s KeyBanc healthcare forum appearance fits this pattern of ongoing business development and investor outreach updates.

Key Terms

cdmo

1 terms

cdmo technical

"Lifecore), a fully integrated injectables contract development and manufacturing organization (“CDMO”)"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum.

Details regarding Lifecore’s participation are as follows:

• 6^th Annual KeyBanc Capital Markets Healthcare Virtual Forum
  Details: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in investor meetings
  Conference Dates: March 17 – 18, 2026
  Fireside Chat Time/Date: 9:00am – 9:35am Eastern Time on Tuesday, March 17, 2026, webcast available
  Location: Virtual

A webcast of the fireside chat may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: https://ir.lifecore.com/events-presentations. Additionally, a replay of the webcast will be available on the Lifecore website following the conference. 

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors & Media)
415-675-7401
sdiaz@vidasp.com

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com

FAQ

When will Lifecore (LFCR) present at the KeyBanc Healthcare Virtual Forum in 2026?

Lifecore will present during March 17–18, 2026, with a fireside chat on March 17 at 9:00am ET. According to the company, the session runs 9:00–9:35am ET and will be available via webcast on its investor website.

How can investors watch the Lifecore (LFCR) fireside chat on March 17, 2026?

Investors can watch the live webcast via Lifecore’s Investor Events & Presentations page. According to the company, a replay will also be posted on the Lifecore website following the conference for later viewing.

Who from Lifecore (LFCR) is scheduled to speak at the KeyBanc forum on March 17, 2026?

Mr. Josephs is slated to be a featured speaker in a fireside chat on March 17, 2026. According to the company, additional Lifecore management will participate in investor meetings during March 17–18.

What topics will Lifecore (LFCR) cover in the KeyBanc fireside chat on March 17, 2026?

The company did not list specific topics in the announcement; the session is described as a fireside chat. According to the company, the chat will feature Mr. Josephs and management engagement with investors during the forum.

Will a replay of the Lifecore (LFCR) KeyBanc presentation be available after March 17, 2026?

Yes, a replay will be available on the company website after the conference. According to the company, the webcast replay will be posted on Lifecore’s Investor Events & Presentations page following the event.